Navigation Links
ERT Files Shelf Registration Statement
Date:11/10/2010

PHILADELPHIA, Nov. 10, 2010 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES), a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, today announced it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC").   While the Company does not have the present intention to conduct an offering of securities registered pursuant to the registration statement, the registration statement, when declared effective by the SEC, will permit the Company to offer and sell from time to time in one or more public offerings up to $150 million aggregate dollar amount of its securities, which may consist of any combination of the Company's debt securities, shares of preferred stock (either separately or represented by depositary shares), common stock and warrants, as well as units that include any of these securities, on terms, in each case, established at the time of the offering.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of such securities under the securities laws of any such jurisdiction.  Any offering may be made only by means of the prospectus included in the registration statement and one or more related prospectus supplements that may be used with respect to such offering.

About eResearchTechnology, Inc.

Based in Philadelphia, PA, eResea
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , December 17, 2014 ... nothing less than a hub of information concerning the biopharmaceutical ... A further addition to the recently launched institutional ... and has now been enriched by a new chapter in ... A richly detailed and panoramic hub on the ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 Henry Schein, Inc. (NASDAQ: ... services to office-based practitioners, announced today that Ferdinand ... the CL King 9th Annual Best Ideas Conference 2011. The ... New York City. Henry Schein,s presentation is ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, reported positive data from a recently ... dual inhibitor of the sodium glucose transporters 1 and ... effects on multiple parameters of glycemic control and cardiovascular ...
Cached Medicine Technology:Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 3LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 HeartMath® ... authorities on stress, heart rate variability (HRV), heart ... licensing its extensive HRV databases and algorithms to ... opportunities will enable HeartMath’s partners to offer its ... extensive research, as well as its normative HRV ...
(Date:12/17/2014)... In its comprehensive analysis of medical ... Claim Review division have recently identified out-of-network and medical ... savings are achieved on behalf of employer-clients. , ... in savings to Argus each year, with a total ... by Tom Doney, Cypress president and CEO, these in-depth ...
(Date:12/17/2014)... Hill, IL (PRWEB) December 17, 2014 ... 2015 Awards celebrate the best of the best in ... The award is only given to communities and agencies ... through the SeniorAdvisor.com site. Of the nearly 100,000 providers ... this award. Winners of the SeniorAdvisor.com Best of 2015 ...
(Date:12/17/2014)... Dec. 15, 2014 (HealthDay News) -- As gas prices ... deaths, a new study suggests. In times of ... of those riders are inexperienced, the researchers explained. ... California, which has the highest number of motorcycle registrations ... of motorcyclist deaths. The analysis revealed a strong ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Expectant parents should ... and Drug Administration recommends. Use of ultrasound imaging ... is not entirely risk-free, the agency warns. ... harm due to ultrasound imaging and heartbeat monitors, prudent ... is important," Shahram Vaezy, an FDA biomedical engineer, said ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... apologized profusely for trying to smuggle human growth hormones and ... with importing banned substances into Australia in February this year ... ,A Customs search of his luggage at the start ... of the banned human growth hormone product, Jintropin. ...
... Exposure to second hand smoke is harmful for underweight ... babies with a low birth weight (5.5 pounds) have ... as coughing, wheezing and pulmonary infections up to age ... if these children are exposed to second hand smoke, ...
... Huxley has said that, "Although there was support for a ... of heart disease , the relationship is not as strong ... may have on heart disease are dwarfed by other risk ... ,Coronary heart disease is the leading cause ...
... International marathon to mobilize public support for the fight against ... ,The proceeds from the marathon, hosted by the ... Embassy of the United Arab Emirates (UAE), will go to ... ,More than 9000 entrants from around the world, including ...
... undergo chemotherapy, they experience fatigue and disruptions in ... study from the University of Nebraska Medical ... say their findings suggest that health professionals should ... any further medical procedures begin. Between 70 to ...
... looking for ways and means of limiting or even stopping ... complicated . ,Offering a way out Wyeth, US ... and Drug Administration (FDA) is expected to announce its approval ... would be the fourth new oral contraceptive that doesn't follow ...
Cached Medicine News:Health News:Sylvester Stallone Regrets Smuggling Banned Substances to Australia 2Health News:Sylvester Stallone Regrets Smuggling Banned Substances to Australia 3Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 3Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 2Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 3
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... H.pylori gII test is a lateral-flow immuno-chromatographic ... of IgG antibodies specific to Helicobacter pylori ... It utilizes a convenient, non-invasive, and easy ... in the diagnosis of H.pylori infection in ...
... HP is a visually read, qualitative immunochromatographic ... H. pylori, a bacterium that grows in ... ulcer disease and some gastric cancers. FlexSure ... blood or serum samples, provides the physician ...
Medicine Products: